Want to see CHRN full AI Analyst Report?
Top Page
ChronoScale
(NASDAQ:CHRN)
Select Model
Select Model
Rating:48Neutral
Price Target:
$22.00
▲(116.75% Upside)
Action:Reiterated
Date:08/19/26
The score is held back primarily by weak financial performance: large ongoing losses, shrinking equity, and persistent negative operating/free cash flow outweigh healthy gross margins. Technicals are modestly supportive with the stock trading above key moving averages, but momentum is not strong. Valuation offers limited support due to negative earnings and no dividend yield, while corporate events are mixed—liquidity support helps, but restructuring/divestiture adds uncertainty and potential charges.
Positive Factors
Healthy Gross Margins
Sustained gross margins indicate that ChronoScale’s products have viable underlying economics. If revenue scale improves, this margin profile could provide operating leverage and help the company absorb fixed costs more effectively.
Negative Factors
Deep Structural Losses
Losses approaching the scale of revenue show that ChronoScale has not yet achieved a viable operating model. Unless revenue expands materially or costs decline, ongoing losses could continue consuming capital and constrain strategic execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Healthy Gross Margins
Sustained gross margins indicate that ChronoScale’s products have viable underlying economics. If revenue scale improves, this margin profile could provide operating leverage and help the company absorb fixed costs more effectively.
Read all positive factors
ChronoScale Key Performance Indicators (KPIs)
ChronoScale (CHRN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.22B
Dividend YieldN/A
Average Volume (3M)376.62K
Price to Earnings (P/E)―
Beta (1Y)1.31
Revenue Growth-34.08%
EPS Growth26.18%
CountryUS
Employees61
SectorTechnology
Sector Strength88
IndustryInformation Technology Services
Share Statistics
EPS (TTM)-5.39
Shares Outstanding145,214,830
10 Day Avg. Volume380,740
30 Day Avg. Volume376,623
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.32
Price to Sales (P/S)1.64
P/FCF Ratio-1.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.1
Revenue Forecast (FY)$19.38M
ChronoScale Business Overview & Revenue Model
Company Description
ChronoScale Corporation designs and develops a compute platform to support artificial intelligence (AI) workloads. The company focuses on large-scale deployments and provides dedicated compute environments engineered for performance, consistency, ...
ChronoScale Earnings Call Summary
Earnings Call Date:Jul 28, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Negative
The earnings call highlighted significant challenges, including a major decline in revenue and gross margin, alongside an increased net loss. Despite these challenges, there were positive developments in the personal health segment, strategic partnerships, and AI initiatives. However, the financial setbacks appear to overshadow the positive developments.Positive Updates
Growth in Personal Health Segment
Personal Health product revenues grew by more than 50% year-over-year in the first half of 2025, driven by the Ekso Indego Personal device.
Negative Updates
Significant Revenue Decline
Second quarter 2025 revenue of $2.1 million was significantly lower compared to $5 million in the second quarter of 2024, due to delays in Enterprise Health sales.
Read all updates
Q2-2025 Updates
Positive
Negative
Growth in Personal Health Segment
Personal Health product revenues grew by more than 50% year-over-year in the first half of 2025, driven by the Ekso Indego Personal device.
Read all positive updates
Company Guidance
During the Ekso Bionics Second Quarter 2025 Financial Results Conference Call, the company reported a disappointing revenue of $2.1 million, a significant drop from $5 million in the same quarter of 2024, primarily due to short-term delays in completing multi-device Enterprise Health sales. Despite this decline, Ekso Indego Personal device sales partially offset the loss. Gross profit for Q2 2025 was $800,000, with a gross margin of approximately 40%, down from a gross profit of $2.6 million and a gross margin of 53% in Q2 2024. Operating expenses were reduced by 4% to $4.8 million. The net loss applicable to common stockholders increased to $2.7 million or $1.24 per share, from $2.4 million or $1.99 per share in the previous year. The company held $5.2 million in cash and restricted cash as of June 30, 2025. Ekso remains optimistic about closing deferred sales and expects Personal Health product revenues to grow significantly, having already increased by over 50% in the first half of 2025 compared to the previous year.ChronoScale Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
14
Very Negative
| Breakdown |
|---|
Income Statement |
| Total Revenue |
| Gross Profit |
| EBITDA |
| Net Income |
Balance Sheet |
| Total Assets |
| Cash, Cash Equivalents and Short-Term Investments |
| Total Debt |
| Total Liabilities |
| Stockholders Equity |
Cash Flow |
| Free Cash Flow |
| Operating Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
ChronoScale Technical Analysis
Positive
10.15
Price Trends
21.51
Positive
17.39
Positive
12.57
Positive
Market Momentum
>-0.01
Negative
55.50
Neutral
59.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CHRN, the sentiment is Positive. The current price of 10.15 is below the 20-day moving average (MA) of 21.57, below the 50-day MA of 21.51, and below the 200-day MA of 12.57, indicating a bullish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 55.50 is Neutral, neither overbought nor oversold. The STOCH value of 59.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CHRN.
ChronoScale Risk Analysis
ChronoScale disclosed 39 risk factors in its most recent earnings report. ChronoScale reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ChronoScale Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
55 Neutral | $43.30M | -10.23 | -149.08% | ― | 3.72% | 43.78% | |
48 Neutral | $3.22B | -2.65 | -177.40% | ― | -34.08% | 26.18% | |
47 Neutral | $29.59M | -2.79 | -92.01% | ― | -1.06% | 82.17% | |
45 Neutral | $6.03M | -0.52 | -83.38% | ― | 72.50% | 58.34% |
* Technology Sector Average
CHRN
ChronoScale
23.53
20.43
659.03%
HBIO
Harvard Bioscience
6.97
2.10
43.12%
MLSS
Milestone Scientific
0.49
-0.11
-17.83%
LUCY
Innovative Eyewear, Inc.
0.71
-1.21
-62.97%
ChronoScale Corporate Events
Business Operations and StrategyExecutive/Board Changes
ChronoScale confirms CFO role with new compensation package
Positive
Aug 18, 2026
On August 16, 2026, ChronoScale Corporation entered into an Offer of Continued Employment and a Covenants Agreement with Chief Financial Officer Jerome Wong, confirming his role and setting his annual base salary at $400,000 with a target performa...
Business Operations and StrategyExecutive/Board Changes
ChronoScale Appoints New Director and Reshapes Board Committees
Neutral
Jun 30, 2026
On June 29, 2026, ChronoScale Corporation expanded its board of directors from seven to eight members and appointed Andrew Cordell Schaap as a director, effective the same day. Schaap was also named to the Audit Committee, replacing Douglas Miller...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
ChronoScale Secures $100 Million Related-Party Credit Line
Positive
Jun 26, 2026
On June 26, 2026, ChronoScale Corporation entered into an unsecured demand grid promissory note with Applied Digital Corporation, establishing a flexible line of credit of up to $100 million, adjusted for any credit support previously provided. Th...
Business Operations and StrategyM&A Transactions
ChronoScale Divests Ekso Bionics to Refocus on Cloud
Negative
Jun 4, 2026
On May 29, 2026, ChronoScale Corporation’s board approved a plan to divest its wholly owned subsidiary Ekso Bionics, Inc., which had not previously been disclosed as held for sale. The move marks a strategic pivot to focus the company’...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.